DNA Methylation and Arsenic-associated Urothelial Carcinoma
|ClinicalTrials.gov Identifier: NCT01360723|
Recruitment Status : Unknown
Verified May 2011 by China Medical University Hospital.
Recruitment status was: Recruiting
First Posted : May 26, 2011
Last Update Posted : May 27, 2011
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||600 participants|
|Observational Model:||Case Control|
|Official Title:||Comparison of DNA Methylation Between Urothelial Carcinoma and Healthy Controls|
|Study Start Date :||May 2011|
|Estimated Primary Completion Date :||May 2014|
Pathological verification of UC was done by routine urological practice including endoscopic biopsy or surgical resection of urinary tract tumors followed by histopathological examination by board-certified pathologists.
Healthy controls group
Age and gender matched control subjects with no evidence of UC or any other malignancy were accrued from the hospital, recruiting people receiving adult health examinations at China Medical University Hospital.
- urothelial carcinoma [ Time Frame: up to three years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01360723
|Contact: Chao-Hsiang Chang, PhD||886-4-22052121 ext email@example.com|
|Department of Urology, China Medical University Hospital||Recruiting|
|Taichung, Taiwan, 404|
|Contact: Chao-Hsiang Chuang, PhD 886-4-22052121 ext 4439 firstname.lastname@example.org|
|Principal Investigator: Chi-Jung Chung, PhD|
|Principal Investigator:||Chi-Jung Chung, PhD||Department of Health risk Management, China Medical University|